Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Prostatic Neoplasms 36Prostatic Neoplasms, Castration-Resistant 5Neoplasm Metastasis 5Metastatic Castration-Resistant Prostate Cancer 4Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Diseases 2Prostate Adenocarcinoma 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sleep Initiation and Maintenance Disorders 1Recurrence 1Prostate Cancer Metastatic 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoadjuvant Therapy 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate-Resistant Prostate Cancer 1Mesothelioma, Malignant 1Melanoma 1

Interventions

Cyclophosphamide 27fludarabine 18Rituximab 17obinutuzumab 11venetoclax 9Bendamustine Hydrochloride 9Lenalidomide 8zanubrutinib 6Prednisone 6Doxorubicin 6Blood Specimen Collection 6pembrolizumab 5fludarabine phosphate 5Biopsy 5ibrutinib 4glofitamab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4Exercise 4loncastuximab tesirine 3gamma-Globulins 3axicabtagene ciloleucel 3acalabrutinib 3Temozolomide 3Surveys and Questionnaires 3Palliative Care 3Mycophenolic Acid 3Methotrexate 3Mesna 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma × enzalutamide × Clear all
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡